SUSQUEHANNA INTERNATIONAL GROUP, LLP - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 89 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2022. The put-call ratio across all filers is 1.18 and the average weighting 0.0%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2023$541,575
-7.6%
205,922
+24.0%
0.00%
Q2 2023$586,015
-65.1%
166,010
-69.4%
0.00%
Q1 2023$1,679,094
+2.7%
543,396
+40.6%
0.00%
Q4 2022$1,635,360
+192.0%
386,610
+63.6%
0.00%
Q3 2022$560,000
-10.8%
236,325
+7.2%
0.00%
Q2 2022$628,000
+21.0%
220,524
+22.4%
0.00%
Q1 2022$519,000
-71.9%
180,121
-70.4%
0.00%
Q4 2021$1,850,000
+119.2%
608,662
+405.7%
0.00%
Q3 2021$844,000
-21.9%
120,357
+2.2%
0.00%
Q2 2021$1,081,000
-9.0%
117,762
-3.6%
0.00%
Q1 2021$1,188,000
-71.7%
122,203
-70.2%
0.00%
Q4 2020$4,202,000
+88.3%
409,696
+85.2%
0.00%
Q3 2020$2,232,000
-11.8%
221,207
-8.9%
0.00%
Q2 2020$2,532,000
-36.2%
242,743
-48.4%
0.00%
-100.0%
Q1 2020$3,969,000
-16.9%
470,263
-13.9%
0.00%
-50.0%
Q4 2019$4,777,000
-39.8%
545,971
-25.9%
0.00%0.0%
Q3 2019$7,936,000
-45.5%
737,289
-35.7%
0.00%
+100.0%
Q2 2019$14,570,000
-28.1%
1,146,351
+119.5%
0.00%
-87.5%
Q1 2019$20,259,000
+157.5%
522,250
+35.1%
0.01%
+100.0%
Q4 2018$7,867,000
-77.4%
386,576
-49.0%
0.00%
-66.7%
Q3 2018$34,737,000
-59.6%
757,617
-47.8%
0.01%
-60.0%
Q2 2018$85,889,000
+93.5%
1,452,054
+122.6%
0.03%
+87.5%
Q1 2018$44,395,000
-59.2%
652,392
-40.7%
0.02%
-57.9%
Q4 2017$108,688,000
+31.4%
1,099,521
+59.2%
0.04%
+18.8%
Q3 2017$82,702,000
-26.4%
690,622
-46.3%
0.03%
-36.0%
Q2 2017$112,309,000
+666.1%
1,285,000
+226.1%
0.05%
+525.0%
Q1 2017$14,660,000
+157.3%
394,100
+112.3%
0.01%
+166.7%
Q4 2016$5,698,000
-71.4%
185,600
-37.5%
0.00%
-70.0%
Q3 2016$19,914,000
+469.0%
297,000
+152.8%
0.01%
+400.0%
Q2 2016$3,500,000
+47.7%
117,500
+45.6%
0.00%
+100.0%
Q1 2016$2,370,000
-80.0%
80,700
-46.6%
0.00%
-80.0%
Q4 2015$11,844,000
-43.6%
151,066
-45.8%
0.01%
-44.4%
Q3 2015$20,997,000
-58.5%
278,639
-35.7%
0.01%
-57.1%
Q2 2015$50,616,000
+25.4%
433,535
+153.5%
0.02%
+16.7%
Q1 2015$40,378,000
-32.9%
171,015
-46.2%
0.02%
-25.0%
Q4 2014$60,158,000
-49.2%
317,842
-36.0%
0.02%
-46.7%
Q3 2014$118,524,000
+312.4%
496,811
+14.1%
0.04%
+246.2%
Q2 2014$28,738,000
+42.7%
435,422
+125.1%
0.01%
+30.0%
Q1 2014$20,143,000
+84.2%
193,413
+83.1%
0.01%
+100.0%
Q4 2013$10,933,000105,6090.01%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q2 2022
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,300,000$12,636,0002.61%
AIGH Capital Management LLC 964,590$9,376,0001.97%
Worth Venture Partners, LLC 226,758$2,204,0001.07%
Camber Capital Management LP 2,555,000$24,835,0000.85%
Palo Alto Investors LP 1,392,997$13,540,0000.77%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,769,795$36,642,0000.77%
GLOBEFLEX CAPITAL L P 428,680$4,167,0000.76%
Zebra Capital Management LLC 34,243$333,0000.37%
Sofinnova Investments, Inc. 344,917$3,353,0000.20%
RICE HALL JAMES & ASSOCIATES, LLC 605,792$5,888,0000.19%
View complete list of PUMA BIOTECHNOLOGY INC shareholders